MK-0773
Aliases: PF-05314882
Last verified: 2026-09-23
The short version
A Merck/Pfizer SARM tested in women with sarcopenia — improved muscle function but without sufficient clinical benefit; discontinued. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Phase IIa sarcopenia (2010); development halted. Status: discontinued. Not approved; WADA-banned (S1).
Identity & type
- Molecular type
- SARM
- Origin
- A Merck/Pfizer SARM tested in women with sarcopenia — improved muscle function but without sufficient clinical benefit; discontinued.
Mechanism of action
Selective AR agonism, 4-aza steroidal structure.
not confirmed in humans
Dosing & routes
Official / clinical context
Development was abandoned; no active regulatory document exists. There are no official indications.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Trials: 50 mg twice daily (women). No community experiences; a historical program for female sarcopenia.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
No community experiences; a historical program for female sarcopenia.
Protocol — official vs community
Official / label
No official protocol exists — this compound has no approved product.
Community (anecdotal)
Structured protocol data for this entry is coming.
Human evidence
Human data are limited: small trials or case-series reports exist, without large randomized studies. Phase IIa sarcopenia (2010); development halted.
Preclinical evidence
Phase IIa sarcopenia (2010); development halted.
Known risks
- Transaminase elevation in some.characterized
- WADA prohibition (S1 anabolic agents)characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- Long-term human safety
- Optimal dose and pharmacokinetics
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.